Literature DB >> 20975386

ILD during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer.

Stephanie-Jayne Jones, Tsveta Milenkova.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20975386     DOI： 10.1097/JTO.0b013e3181f18e53

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  2 in total

1.  Fatal interstitial lung disease after addition of sorafenib to a patient with lung adenocarcinoma who had failed to improve with erlotinib alone.

Authors:  Yin Guan; Jing Meng; Hong Zhao; Yi Hu; Xiang Yan; Shao-Hong Zhao; Shun-Chang Jiao
Journal:  Case Rep Oncol       Date:  2014-04-25

Review 2.  The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology.

Authors:  Nagahiro Saijo
Journal:  Yonsei Med J       Date:  2013-01-01       Impact factor: 2.759
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.